MDR-001
Sources
registry, as of 2025-12-22Stale
https://clinicaltrials.gov/study/NCT07274137
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor MindRank AI Ltd. Enrollment 738. Conditions Overweight or Obesity. This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal
ClinicalTrials.gov NCT07274137 protocol and results modules
registry, as of 2024-09-24Stale
https://clinicaltrials.gov/study/NCT06606483
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight. Overall status UNKNOWN. Phases PHASE2. Lead sponsor MindRank AI Ltd. Enrollment 300. Conditions Obesity; Overweight and Obesity. This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesit
ClinicalTrials.gov NCT06606483 protocol and results modules
registry, as of 2026-09-18Stale
https://clinicaltrials.gov/study/NCT06778850
A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor MindRank AI Ltd. Enrollment 128. Conditions Overweight and Obese Volunteers. To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.
ClinicalTrials.gov NCT06778850 protocol and results modules
registry, as of 2025-08-08Stale
https://clinicaltrials.gov/study/NCT07110766
Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor MindRank AI Ltd. Enrollment 24. Conditions Obesity &Amp; Overweight. This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity
ClinicalTrials.gov NCT07110766 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT07274137
placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MD
NCT07274137 description or intervention text